Background. Maternal antibodies to pertussis can hamper infant immune responses to pertussis vaccines. The effect a maternal tetanus, diphtheria, acellular pertussis (Tdap) vaccine booster between 2 consecutive pregnancies is investigated.
Despite universal infant vaccination programs against Bordetella pertussis, there is an increase in reported whooping cough cases, particularly in industrialized countries. Most outbreaks occur in adolescents and young adults [1] , who represent a source of infection for unvaccinated infants and newborns. The highest incidence of pertussis is recorded in very young children who have not yet been (fully) vaccinated and/or did not receive sufficient maternal antibodies [2] .
At first, cocoon vaccination was recommended to protect young infants from disease, but cost-effectiveness studies, as well as difficulties in reaching high coverage among all persons in contact with young infants, discouraged the strategy [3] . Since 2012, maternal vaccination during pregnancy has been recommended in an increasing number of (industrialized) countries as a strategy to protect young infants from disease.
Many countries advise to immunize at every pregnancy, since antibodies rapidly wane after an adult booster dose [4] and because a high concentration of maternal antibodies is needed to transfer antibodies from mother to fetus during pregnancy [5] . For pertussis, a correlate of protection is not well defined, yet high concentrations of antibody to pertactin (Prn) and, mainly, antibody to pertussis toxin (PT) are related to protection [6] . After birth, levels of maternal antibodies decrease rapidly in the offspring, mostly within 2 months [7] .
The present article reports results of a prospective study on the transfer and persistence of maternal antibodies in newborns, whenever a tetanus, diphtheria, and acellular pertussis (Tdap) booster vaccination is given to women between 2 consecutive pregnancies. Previously, we reported an interim analysis on a subsample of this cohort study [8] . The primary aim of the study is to evaluate whether a prepregnancy booster helps increase antibody concentrations to pertussis in neonates, thereby possibly closing the susceptibility gap. A secondary aim is to evaluate possible blunting of the infant immune responses to pertussis-containing vaccines after a prepregnancy maternal booster vaccination, similar to the blunting of the infant immune responses after Tdap vaccination during pregnancy [9] . In addition, modeling the anti-PT immunoglobulin G (IgG) antibody concentrations enables drafting possible recommendations regarding the timing of consecutive maternal booster doses.
A prospective multicenter study was conducted in Antwerp, Belgium, between 2008 and 2014, in accordance with the Helsinki Declaration, the International Conference on Harmonisation guideline on good clinical practice, and procedures established by Belgian law. Ethical approval was obtained (from University Hospital of Antwerp). Women participating in a study on maternal antibody kinetics were recruited [10] [11] [12] . Participating women provided informed consent; informed consent for participating children was obtained from their parents. For the women, the exclusion criteria were pertussis vaccination within 10 years prior to study participation, immunological disorders, and recent administration of immunoglobulins prior to vaccination. Exclusion criteria for the children were low birth weight (<2400 g), prematurity (<36 weeks of gestation), and immunological disorders. Serum samples were collected from all women at delivery (10 mL), from the cord (10 mL), and from the infant at 1 month of age, 6 or 9 months of age (the age was selected at random), and 12 months of age (2 mL per specimen; group A). Time points were chosen on the basis of the waning of maternal measles virus antibodies [10] .
Women were offered Tdap vaccine after the first delivery. One month after vaccination, a blood sample (10 mL) was collected. At the consecutive delivery, blood specimens were again collected from woman and the cord, with specimens collected from the sibling at 1 month of age, 6 or 9 months of age (at the same age as that of the older sibling), and 12 months of age (group B).
All infants were vaccinated according to the standard Belgian vaccination schedule with hexavalent acellular pertussis-containing vaccine at 8, 12, and 16 weeks. An extended questionnaire collected information on obstetrical risk factors, demographics, vaccination history, and general medical history. Growth parameters, breastfeeding data, immunization data, and medical history were collected at each visit.
Study Vaccines
Licensed Tdap vaccine (Boostrix; GSK Biologicals, Rixensart, Belgium) was used to immunize women in the deltoid muscle. 
Laboratory
All serum samples were centrifuged at 1100 g within 24 hours after withdrawal and were stored between −20°C and −40°C.
Leftover serum specimens from women and infants in group A were selected for analysis in view of the inclusion of their siblings (ie, group B infants). An in-house enzyme-linked immunosorbent assay (ELISA) was used to test all samples for anti-PT, anti-FHA, and anti-Prn IgG antibodies at GSK Biologicals. The limit of detection of the assay was 5 Elisa Units (EU)/mL for all 3 antibodies. For women, a booster response was defined as a postvaccination antibody concentration of ≥20 EU/mL among those with a prevaccination concentration of <5 EU/mL, a postvaccination antibody concentration that was 4 times the prevaccination concentration among those with a prevaccination concentration of ≥5 EU/mL and <20 EU/mL, or a postvaccination antibody concentration that was ≥2 times the prevaccination concentration among those with a prevaccination concentration of ≥20 EU/mL. The prevaccination concentration was measured in the maternal sample taken at the time of the first delivery.
Statistics
Antibody geometric mean concentrations (GMCs) with 95% confidence intervals were calculated. Statistical tests included parametric tests (paired or unpaired t tests and χ 2 tests) and their nonparametric alternatives (paired or unpaired Wilcoxon tests and Fisher exact tests, respectively). The analysis was performed using SPSS statistical software, version 23.0.
Nonlinear mixed-effects models (NLMMs) were used to model the dynamics of anti-PT antibodies in both mothers and infants. Anti-PT antibodies were chosen because they, as well as anti-Prn antibodies, correlate with protection [13] . The model building procedure is described in the Supplementary Materials. The models were fitted using Monolix software [14] . Anti-PT antibody values of <5 EU/mL are treated as leftcensored data. Results of the NLMMs are expressed as medians and interquartile ranges (IQRs) because of possible asymmetry for the quantities under study, as well as for ease of interpretation. Supplementary Figure 1 shows a presumed visualization of the dynamics of the anti-PT antibody levels in the infants, indicating the different slopes and rates, used in the NLMM model. Finally, a robust simple linear regression model was fitted to investigate the association between the antibody levels in women at delivery and in the cord.
All rates mentioned in the article are exponential decay or growth rates expressed in months, unless indicated differently. A significance level of 5% was used for all analyses. Blunting of vaccine immune responses was defined as a significantly lower GMC of PT-specific IgG antibodies in group B siblings.
RESULTS

General Characteristics of the Study Population
In total, 86 women received a Tdap vaccination after a first pregnancy. All women had been vaccinated against pertussis during childhood, using whole cell pertussis-containing vaccines, and had received no documented pertussis booster for at least 10 years prior to the study booster. Of the 86 vaccinated women, 58 became pregnant again and delivered within the study period.
The median interval between the first delivery and the Tdap vaccination was 16.07 months (range, 8.46-43.31 months). The median interval between the Tdap booster and the consecutive delivery was 16.80 months (range, 6.20-56.49 months). Three women had a negative pregnancy test result at the time of vaccination but were pregnant 1 month later, despite contraceptive advice. The mean age of the women was 29.97 years at the first delivery and 32.04 years at the consecutive delivery. The mean durations of both pregnancies were comparable. No significant difference in birth weight and length of both siblings was seen, nor was there a significant difference in the ratio of males to females (Table 1) . Table 2 summarizes the GMC of IgG antibody concentrations to PT, FHA, and Prn in all women at the first delivery (ie, in the prevaccination sample), 1 month after booster vaccination, and at the moment of delivery of the group B siblings. At baseline, 93% of the women had detectable anti-FHA IgG antibodies, and 79% had detectable anti-Prn IgG antibodies, while 52% had anti-PT IgG antibody concentrations of >5 EU/mL. A total of 16% of participating women were seronegative for both anti-PT and anti-Prn antibodies at baseline. One month after vaccination, 97.7% of the women showed a booster response to FHA and Prn, while 90.7% showed a booster response to PT. All but 1 woman responded with a rise in levels of all pertussis-specific antibodies, and there were no differences in the magnitude of anti-PT responses and anti-Prn responses between seronegative women and seropositive women before vaccination. At the next delivery, the mean maternal antibody levels for all 3 antigens had declined significantly (P < .001), compared with levels 1 month after vaccination, but they were still significantly higher than baseline concentrations for all antibodies (P < .001). In 8 women, the anti-PT antibody concentration dropped below the threshold of 5 EU/mL at the consecutive delivery. Table 3 shows the transplacental transport ratio in both cohorts of infants. In general, the GMC in cord blood exceeded the GMC in the mother at delivery for both siblings. Ratios did not significantly differ at consecutive pregnancies.
Laboratory Results
Maternal Results
Cord Results
Infant Results
Group B siblings had significantly higher antibody levels to all pertussis-specific antigens at birth as compared to group A infants; the differences lasted up to the age of 1 month, before the start of the infant vaccination program. After receiving the 3 doses of the primary vaccination series, all antibody concentrations were consistently lower in group B siblings (month 6). For anti-FHA and anti-Prn, the IgG concentrations were significantly lower at the ages of 9 and 12 months. For anti-PT, on the other hand, the antibody concentrations were only significantly lower at the age of 12 months (Table 2) .
Modeling Results
Maternal Results
Based on the NLMM, the median time for anti-PT antibodies in women to decrease by 50% (ie, the half-life) was 15.87 months (IQR, 14.86-16.74 months). The age of the mother at vaccination had no significant effect on this half-life. Since there is no correlate of protection for pertussis, it is unclear how high the maternal antibody concentration at delivery should be to protect the offspring. Figure 1 shows the median times ( IQRs) 
Infant Results
The results of the NLMM confirm that siblings in group B had a significantly higher antibody concentration at birth (denoted by A 0 in Figure of the Supplementary Materials), compared with group A infants. After birth and before the start of the infant vaccination program, maternal antibody levels decreased very fast in both groups (Figure 2 ): the median time for anti-PT antibody levels in group A infants to fall below 5 EU/mL was 1.21 months (IQR, 1.08-1.36 months), while it took about 2.21 months (IQR, 2.09-2.39 months) for anti-PT antibody levels to drop below 5 EU/mL in group B siblings. The half-life of maternal anti-PT antibody levels in infants was approximately 5 weeks (33 days and 30 days for group A and B infants, respectively). Infants in group B had a significantly lower rate of increase (denoted by γ in Figure of the Supplementary Materials) of anti-PT IgG antibody levels after priming with 3 vaccine doses. The time point, h, at which we observed the highest antibody concentration before waning of antibodies, was estimated to be 6.82 months (IQR, 6.63-7.01 months). The last scheduled vaccine dose was administered at 16 weeks of age, but the effect of 3 subsequent primary doses made the antibody levels continue to increase approximately 2.82 months after the last dose.
We included the sex ratio and birth weight of the infants, centered around their mean values, in the NLMM: boys were born with significantly higher anti-PT antibody concentrations as compared to girls in both groups. Time point h in boys was significantly lower (5.55 months; IQR, 5.33-5.77 months), compared with the estimated value of h for girls (7.06 months; IQR, 6.84-7.28 months). Newborns with higher birth weight tended to have higher estimated decay rates (denoted by β  ), although this small difference was not clinically relevant.
Correlation Between Maternal and Infant Antibody Levels
The robust simple linear regression model shows a significant positive association between the anti-PT IgG antibody levels in women at delivery and in the cord. The predicted anti-PT IgG antibody levels in the cord of the infant whose mother had anti-PT IgG antibody levels at delivery of 5, 10, 15, 20, and 25 EU/mL were 10.43 EU/mL (IQR, 9.31-11.55 EU/mL), 18 To evaluate the possible interval between several booster doses of Tdap in 1 woman, the correlation of maternal antibody levels at delivery with titers in cord and with loss of these maternal antibodies in the young infant over time (as a measure for protection from disease) could offer insights about the need for repeat booster and the presence of possible interference of infant immune responses on vaccines. If, at delivery, the anti-PT antibody titer in the mother is 15 EU/mL, it takes roughly 2.5 months in infants for anti-PT antibody levels to decline below 5 EU/mL and 1 month for levels to fall below 10 EU/mL ( Figure 2 ).
DISCUSSION
At baseline, 48% of the women in the present long-term follow up study had undetectable anti-PT antibody levels, indicating the lack of maternal antibodies available for transfer and, hence, the lack of protection offered at birth. After women received a prepregnancy Tdap booster vaccination, they had good humoral responses. Yet, similar to findings from other studies of Tdap vaccine in adults [15] [16] [17] , a rapid drop in antibody concentrations was measured after vaccination: the half-life of antibodies to PT was estimated to be 15.87 months. However, median antibody concentrations remained significantly higher in women at the next delivery, even if the booster dose was offered >2 years before the consecutive delivery. And significantly increased concentrations of maternal antibodies specific to pertussis were still encountered in that offspring, who was born after the mother received the booster dose. In 13% of women (8 of 58), the level of anti-PT IgG had declined below the lower limit of 5 EU/mL by the next delivery, indicating possible susceptibility to disease for the young infant and underlining the importance of repetitive boosting with each new pregnancy. Transplacental maternal antibody transport in children born before and after the prepregnancy booster vaccination was equally effective. Previously, adequate transport has been described in prospective cohorts [9, 18, 19] . Yet, this is the first study describing transplacental transport in siblings, and no effect of vaccination or parity was found on the adequacy of the transport. We stress that our cohort consisted of healthy pregnant women with mostly healthy pregnancies, while transplacental transport can be influenced by placental dysfunction or disease. We confirm in the present study the recently published Swiss data that the presence of high titers of maternal antibodies during the entire pregnancy, or a long period thereof, results in adequate transport and high concentrations of maternal antibodies at birth [20] .
Using a NLMM, we calculated the impact of the time between repeat boosters in healthy adult women on the levels of antibody transferred to the fetus. Based on these results, the interval between consecutive pertussis booster vaccines should be no longer than 30 months (roughly 2.5 years), to have median concentrations of antibody to pertussis toxin in pregnant women as high as 15 EU/mL at the moment of delivery. This level corresponded to anti-PT IgG antibody levels in cord blood of 26.53 EU/mL in the present study (IQR, 23.87-29.19 EU/mL). These results are based on the assumptions that the estimated decay rate derived from our model is the same as the one we would obtain with a larger number of samples (Supplementary Materials) and that the positive effect that we found in group B siblings is protective against disease. This interval is not a recommendation; rather, it is a finding that has to be confirmed on the basis of results of additional persistence studies, possibly including information on antibody levels at multiple time points to inform antibody dynamics. In addition, similar calculations when vaccination is offered during pregnancy are needed and planned.
Infants born after a pre-pregnancy booster had significantly higher anti-PT GMCs at birth that endured up to 1 month of age, thus closing potentially the interval of susceptibility to infection. These results are in line with those on the effect of Tdap vaccination during pregnancy [9, 18, 19] . The median half-life of anti-PT IgG antibodies in infants was relatively short (5 weeks), which is again in line with literature [21] [22] [23] . Since no correlate of protection is known for pertussis [13] , it is unclear whether the elevated antibody concentrations in the second-born cohort are sufficiently protective against disease or whether the blunting later in infant life, after a primary series of 3 vaccines, is meaningful in terms of protection. Indeed, the effect of these maternal antibodies on the immune responses to the primary infant vaccination is still detectable in group B siblings born after a prepregnancy booster dose. This so-called blunting effect has been described after maternal Tdap vaccination during pregnancy [9, 18, 19, 24] , but this is the first study to describe the same effect after a prepregnancy (or postpartum) booster dose. What we have measured is the effect of cocoon vaccination on an infant born later on. Effectiveness data are lacking with regard to whether the elevated titer of maternal antibodies is protecting young infants from disease.
At months 6 and 9 of age, after primary vaccination, differences between both siblings are not always significant for all 3 tested antibody types, perhaps because of the small sample size. GMCs measured in previous studies in infants at 12 months of age [25] are comparable to GMCs in children at 1 month of age after a prepregnancy booster, suggesting that GMCs in group B siblings at birth would be compatible with clinical protection. The present study also shows that countries that recommend cocoon vaccination or repeated boosters should be aware that significantly higher antibody concentrations are transferred to offspring, thereby leading to possible early life protection but also to potential interference of maternal antibodies with the infant's immune response. Data could be used for cost-benefit calculations for subsequent doses in women of childbearing age.
There are a few shortcomings in this study. There was a rather low number of infants born after the booster dose as a result of the difficulty to plan this upfront. Besides, the study was not powered to detect small differences in antibody levels between both siblings with regard to the increasing interval between vaccination and delivery of a second-born child. In addition, the time points of blood sample collection were chosen according to the original study on measles virus antibody kinetics, and those were likely not the most optimal time points for measuring response to pertussis antigens. Nevertheless, prevaccination and postvaccination samples were available and were always collected at the same time points. To better understand the relevance of the findings, measurement of the functionality of the antibodies would be valuable and, ideally, would compare the functionality of antibodies elicited during pregnancy and, as in this project, when women are not pregnant.
To conclude, the present study is the first to describe the effects of a prepregnancy Tdap booster vaccine and compared the kinetics of anti-PT antibodies between siblings born before and after the booster dose. The maternal antibodies at birth were significantly higher in the second-born siblings, even with a growing interval between booster and subsequent delivery.
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